Johnson & Johnson JNJ · USD
Health Care · Pharmaceuticals · US listing · 🇺🇸 United States
S&P 500Dow Jones
276.22
+1.43%
Close of 6 Nov 2026, in USD
About Johnson & Johnson
From its filings with the US Securities and Exchange Commission
Johnson & Johnson is based in New Brunswick, New Jersey and is incorporated in New Jersey. Its shares trade on NYSE under the ticker JNJ. It is a member of the S&P 500 and Dow Jones. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 28 December 2025, it reported revenue of $94.19bn and net income of $26.80bn. At that date it held total assets of $199.21bn and shareholders' equity of $81.54bn. By region, United States accounted for 57.1%, followed by Non-US at 42.9%.
Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
The Chief Operating Decision Maker (CODM) is the Company's Chief Executive Officer (Principal Executive Officer). The Executive Committee is Johnson & Johnson’s senior leadership team responsible for setting the strategy and priorities of the Company and driving accountability at all levels. Within the strategic parameters provided by the Executive Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.
The MedTech segment develops and manufactures a broad portfolio of products used in cardiovascular, orthopaedics, surgery, and vision supporting physicians, hospitals, eye care professionals and healthcare systems across a wide range of acute and elective procedures. These products are designed to address disease states where procedural intervention plays a central role in treatment and patient outcomes.
Quoted from its 10-K, filed 11 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Sept 1944
- Employees
- 138,200
- Website
- jnj.com ↗
- Head office
- ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ, 08933
- Incorporated in
- NJ
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Joseph WolkChief Financial Officer, Executive Vice President$12.6m
- Ms. Kristen MulhollandChief Human Resources Officer, Executive Vice President
- Ms. Kathryn WengelExecutive Vice President, Chief Technology Officer and Risk Officer
- Mr. James SwansonExecutive Vice President, Chief Information Officer
- Ms. Vanessa BroadhurstExecutive Vice President - Global Corporate Affairs
- Ms. Elizabeth ForminardExecutive Vice President, Chief Legal Officer
- Prof. Dr. John ReedExecutive Vice President - Innovative Medicine, Research and Development$9.3m
- Mr. Tim SchmidExecutive Vice President, Worldwide Chairman of MedTech$11.9m
- Ms. Jennifer TaubertExecutive Vice President, Worldwide Chairman, Innovative Medicine$11.2m
- Ms. Marillyn HewsonLead Independent Director$409,289
- Mr. Daniel PintoDirector
- Dr. Mary BeckerleIndependent Director$380,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 81
- Environment
- 87
- Social
- 93
- Governance
- 62
- Direct emissions (scope 1)
- 320,104 t
- Energy emissions (scope 2)
- 467,934 t
- Value chain emissions (scope 3)
- 6,865,589 t
- Women in the workforce
- 50.36%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Johnson & Johnson (J&J) possesses several key strengths that contribute to its success in the market. Firstly, the company has a diversified product portfolio spanning various sectors such as healthcare, pharmaceuticals, and consumer goods. This diversification allows J&J to leverage its brand equity and penetrate multiple markets effectively.
- Secondly, J&J has a strong brand reputation built on trust and reliability. The company is known for its high-quality products, which have earned consumer loyalty over the years. This positive brand perception gives J&J a competitive edge and enhances customer trust, leading to continued business growth.
- Additionally, J&J has a vast global presence, operating in multiple countries around the world. This global reach provides the company with access to diverse markets and a broad customer base. It enables J&J to adapt to changing market dynamics and explore new growth opportunities.
Weaknesses
- Despite its strengths, J&J also faces some notable weaknesses. One of the main weaknesses is its dependence on external suppliers for raw materials and components. Any disruption in the supply chain could impact production and result in delays or shortages of J&J products.
- Furthermore, J&J has experienced product recalls and legal issues in the past, which have affected its reputation and financial performance. These incidents highlight a need for stricter quality control measures and regulatory compliance within the organization.
Opportunities
- J&J has several opportunities to capitalize on in the market. One notable opportunity is the growing demand for healthcare and pharmaceutical products, driven by an aging population and increasing healthcare needs globally. J&J can leverage its expertise and expand its product offerings to cater to these emerging market needs.
- Additionally, advancements in technology and digitalization present opportunities for J&J to enhance its product innovation and delivery channels. Embracing digital platforms and integrating technology in its operations can help the company stay competitive and meet changing customer preferences.
Threats
- J&J needs to be aware of several potential threats that may impact its business. One significant threat is increasing competition from both established players and new entrants in the healthcare and pharmaceutical industries. This competition may affect market share and profitability.
- Moreover, evolving regulations and policies in the healthcare sector pose a threat to J&J's operations. Compliance with stricter regulations can increase costs and restrict product development and distribution processes.
- Additionally, the current global economic environment and geopolitical uncertainties may impact consumer spending patterns, which could result in lower demand for J&J products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.